Azenta, Inc. (NASDAQ: AZTA) is a life sciences tools and services company that supplies automated ultra-cold sample storage, repository services, consumables, and multiomics (genomic sequencing and synthesis) to drug developers and research institutions. After a volatile stretch in which the shares traded as low as $15.93, the stock has recovered to roughly $41, raising the question of whether it can extend toward $46.
Azenta does not currently offer a clean, actionable analyst aggregate that sits meaningfully above the share price. Based on data aggregated by Yahoo Finance and StockAnalysis from six analysts, the average 12-month price target is about $37.80, with individual targets spanning roughly $33 to $44. MarketBeat has at times reported a slightly higher seven-analyst average near $41, but that figure also sits essentially at or below the current quote. In other words, the shares have rallied ahead of published expectations.
Because the consensus mean is below the current price, the $46 objective in this article comes from public technical discussion rather than analyst forecasts. Specifically, $46 approximates the stock's 52-week high of $46.41 reached in early October 2026 and represents a round-number resistance zone where prior buyers stepped back. It is a realistic milestone that is publicly discussed, not a brokerage-derived consensus.
With the stock near $40.95, reaching $46 would require upside of roughly 12%, a modest move given Azenta's elevated volatility and a beta near 1.5. The shares have already more than doubled off their 52-week low, so the path to $46 is less about a new fundamental narrative than about sustaining recent momentum through an earnings catalyst and holding above the prior consolidation range.
Fundamentally, Azenta remains loss-making on a GAAP (generally accepted accounting principles) basis, with trailing twelve-month net income near negative $123 million and diluted EPS (earnings per share) around negative $2.67. Its forward P/E (price-to-earnings ratio) is elevated near 86, reflecting expectations for future profitability rather than current earnings. That means the stock is valued on revenue growth, margin progress, and a return to sustained profitability.
The most important overhead reference is the 52-week high of $46.41, a level that marked a sharp reversal in October. Round-number resistance sits near $45. On the downside, the $39–$40 zone acted as recent support, with a more durable floor around $35.55. The shares trade above both their 50-day and 200-day moving averages, reflecting an intact longer-term uptrend, but the proximity of the $46 area makes it a clear test of whether buyers are willing to pay at the top of the recent range.
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms vary. For Azenta, the immediate catalyst is its fiscal fourth-quarter earnings report and forward guidance, followed by any analyst revisions. Investors should also monitor margin progression, free cash flow, the pace of buybacks, sector demand commentary from life sciences peers, and interest-rate and risk-appetite conditions that influence small-cap growth valuations.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, the tool helps traders discover opportunities, monitor existing positions, and spot emerging trends more efficiently. If you are looking for a data-driven way to stay on top of shifting market structure, consider exploring these signals as part of your workflow.
The question of whether Azenta can reach $46 is not about analyst upside — the average analyst target sits below the current price — but about whether the stock can reclaim its 52-week high. A 12% move is modest by Azenta's historical volatility, and the company has real supports in recovering revenue, a strong balance sheet, portfolio focus, and buybacks. Against that, persistent GAAP losses, a large impairment, legal overhangs, and a valuation that has outrun consensus targets argue for caution. Reaching $46 will likely depend on the next earnings report, guidance, and the stock's ability to hold its recent breakout levels rather than on any single valuation metric.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with IQV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | -2.99% | ||
| IQV - AZTA | 60% Loosely correlated | -2.69% | ||
| RVTY - AZTA | 59% Loosely correlated | -0.71% | ||
| A - AZTA | 59% Loosely correlated | -0.40% | ||
| MTD - AZTA | 59% Loosely correlated | -0.83% | ||
| BRKR - AZTA | 58% Loosely correlated | +1.22% | ||
More | ||||
| Ticker / NAME | Correlation To AZTA | 1D Price Change % |
|---|---|---|
| AZTA | 100% | -2.99% |
| Pharmaceuticals: Other industry (49 stocks) | 41% Loosely correlated | N/A |
| Pharmaceuticals industry (151 stocks) | 0% Poorly correlated | +0.84% |